Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial
| Autor: | Herbert W. Kappauf, Klaus Zellmann, Clemens Giessen, W. Abenhardt, Daniel Oruzio, L. Fischer von Weikersthal, J. Mittermueller, Martina Stauch, M. Schulze, Sebastian Stintzing, Volker Heinemann, Gerhard Puchtler, Nicolas Moosmann, H. Dietzfelbinger, Thomas Decker, S. Klein, Holger G. Hass, Ursula Vehling-Kaiser, Christopher Haberl |
|---|---|
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 29:3589-3589 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2011.29.15_suppl.3589 |
| Popis: | 3589 Background: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of two capecitabine-based regimens: CAPIRI plus cetuximab (CAPIRI-C) and CAPOX plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC). Treatment related skin toxicity was evaluated separately for capecitabine and cetuximab. The present analysis investigates the correlation of capecitabine-attributed skin toxicity (Cape-ST) and parameters of treatment efficacy. Methods: mCRC patients were randomized to cetuximab (400mg/m2 day 1, followed by 250mg/m2 weekly) plus CAPIRI (irinotecan 200mg/m2, day 1; capecitabine 800mg/m2 twice daily, days 1-14, every 3 weeks) or cetuximab plus CAPOX (oxaliplatin 130mg/m2 day 1; capecitabine 1000mg/m2 twice daily, days 1-14, every 3 weeks). Results: Of 185 recruited patients, 149 patients (CAPIRI-C, n=78; CAPOX-C, n=71) received study treatment beyond the first tumor assessment and were evaluable for efficacy. While cetuximab-specific skin toxi... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|